demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID 19 outpatients
Immunostimulants drugs
convalescent plasma treatment CONV-ERT CoV-Early ... C3PO
Early convalescent plasma. CoV-Early ...
interferon
inhaled interferon
SNG001 inhaled interferon beta ACTIV-2 SNG001
peginterferon Feld TOGETHER interferon lambda
neutralizing antibody Webb
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-2 ...
bamlanivimab monotherapy Rainwater-Lovett Bariola BLAZE-1 phase 2 ... OPTIMISE-C19 ...
bamlanivimab/etesevimab BLAZE-4 BLAZE-1 phase 2 ... BLAZE-1 phase 3 ... OPTIMISE-C19 ...
Bebtelovimab (LY-CoV1404) BLAZE 4 LY-CoV1404
casirivimab/imdevimab (Ronapreve) Cov-2067 Weinreich ... Mazzotta Cov-2069 ...
cilgavimab and tixagevimab (Evusheld) TACKLE
regdanvimab (Regkirona- CT-P59-Celltrion) CT-P59 3.2 part 2 CT-P59 3.2 part 1
sotrovimab (Xevudy; VIR-7831) COMET-ICE

7 studies excluded by filtering options 2

5405 Ahn, 2020 200excludedrisk of bias not avaialble
5408 Shen, 2020 200excludedrisk of bias not avaialble
5409 Ye, 2020 200excludedrisk of bias not avaialble
5410 Zhang, 2020 200excludedrisk of bias not avaialble
5411 Zhang, 2020 200excludedrisk of bias not avaialble
5569 Dai W, 2020 2134excludednot a RCThigh risk of bias
10178 Bargay-Lleonart, 2022 210excludedrisk of bias not avaialble